Treatment Patterns and Clinical Outcomes in Unresectable Stage III EGFR-Mutated Non-Small Cell Lung Cancer in China.

Adv Ther · 2026 · PMC13065558 · PMID 41697515

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a favorable trendno p-value reported

An updated overall survival (OS) analysis (maturity 31%) from LAURA showed a favorable trend for OS benefit with osimertinib over placebo: median OS with osimertinib was 58.8 months (95% CI 54.1–NC) and was 54.0 months with placebo (95% CI 42.1–NC); HR 0.67 (95% CI 0.40–1.14, p = 0.140) [ 23 ].

also in 993 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.